This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SLC39A10 / Zinc transporter ZIP10 · IHC design guide
Design Immunohistochemistry for SLC39A10
Plan SLC39A10 paraffin IHC using strongly stained ciliated cell bodies as reference tissue (HPA tissue IHC). This guide covers the observed cytoplasmic and membranous pattern (HPA tissue IHC), fixation, controls and the catalog antibody’s 2–5 μg/mL IHC range (datasheet A09043-1).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SLC39A10 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and membranous tissue staining (HPA tissue IHC) | |
| Staining pattern | Ciliated cell bodies: high; tissue signal cytoplasmic/membranous (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A09043-1) | |
| Positive control | Fallopian tube+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A09043-1) | |
| Caveat | Medium staining–RNA consistency; verify the signal (HPA tissue IHC) | |
| Regulation | Expression regulation is not annotated (UniProt) | |
| Isoform / epitope | 2 isoforms; confirm extracellular vs cytoplasmic epitope (UniProt) |
Section 1
Recommended SLC39A10 IHC & IF Protocols
The catalog antibody’s IHC-P protocol (datasheet A09043-1) is accompanied by one published SLC39A10 tissue IHC protocol (PMC8357404).
| Sample | Paraffin-embedded human brest cancer tissue; fixative not specified (datasheet A09043-1) |
| Fixation | Image fixative and duration unreported (datasheet A09043-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A09043-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A09043-1) |
| Primary antibody | Rabbit anti-SLC39A10, 2-5 μg/ml (datasheet A09043-1) |
| Primary incubation | Overnight at 4 °C (datasheet A09043-1) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A09043-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SLC39A10-positive staining in ciliated cells (cell body) of fallopian tube (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and membranous expression in several tissues, including thyroid gland. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 (datasheet A09043-1); compare EDTA pH 9.0 retrieval during optimization (PMC8357404).
Section 2
What Is the Expected SLC39A10 Staining Pattern?
SLC39A10 is a seven-pass membrane protein with a reported apical location in kidney proximal tubules (UniProt Q9ULF5 topology and subcellular location). In paraffin IHC, expect cytoplasmic and membranous staining across several tissues, especially ciliated cells of the fallopian tube and nasopharynx (HPA tissue IHC). HPA rates the tissue profile Approved, with medium consistency against RNA data and external verification pending (HPA tissue IHC).
| Strong cell-body staining in fallopian-tube or nasopharyngeal ciliated cells (HPA tissue IHC: High). | This matches HPA’s strongest listed tissue IHC observations. Assess whether staining follows the expected cells and cytoplasmic or membranous distribution; intensity alone cannot establish specificity (HPA tissue IHC profile; general IHC practice). |
| Only extracellular or luminal chromogen is visible, without staining in the expected cells (HPA tissue IHC profile). | That distribution does not match the reported cellular pattern and may reflect deposited reagent or other artefact (HPA tissue IHC profile; general IHC practice). Inspect an omission control and repeat detection if the deposit persists. |
| Widespread staining appears in glomerular cells or adipocytes (HPA tissue IHC: Not detected in those cells). | This conflicts with the listed HPA observations and warrants a cross-reactivity or endogenous detection check (HPA tissue IHC; general IHC practice). The renal comparison is cell specific: UniProt places SLC39A10 at proximal-tubule apical membranes, not glomeruli (UniProt Q9ULF5 subcellular location). |
| A diffuse haze covers cells, stroma, and clear spaces, obscuring cell boundaries (general IHC practice). | Treat the slide as difficult to score: the haze can arise from nonspecific binding, incomplete washing, or detection background (general IHC practice). Compare an omission control before assigning any apparent SLC39A10-positive cell type. |
| No cell-body signal appears in adequately preserved fallopian-tube or nasopharyngeal ciliated cells (HPA tissue IHC: High). | A known-positive compartment is missing, so a negative study result is not yet interpretable (HPA tissue IHC; general IHC practice). Check section integrity, antibody and detection controls, then optimize routine IHC conditions without assuming a documented SLC39A10 fixation effect. |
💡Expected SLC39A10 appearanceCall a positive IHC result when ciliated-cell bodies show strong cytoplasmic and/or membranous signal in fallopian tube or nasopharynx (HPA tissue IHC: High); isolated luminal deposit or broad acellular haze is suspect (HPA tissue IHC profile; general IHC practice).
| Which cells provide the clearest IHC reference? | Fallopian-tube and nasopharyngeal ciliated cells are listed as High; bronchial ciliated cells, endometrial glands, lung alveolar cells, placental trophoblasts, and prostate and seminal-vesicle glands are Medium (HPA tissue IHC). Use the same cell type when comparing sections. |
| What does membrane topology support? | UniProt annotates seven transmembrane segments and an apical proximal-tubule location (UniProt Q9ULF5 topology and subcellular location). These support a membrane component but do not specify the antibody epitope or predict chromogenic intensity in a particular tissue. |
| Do processing or isoforms alter this call? | UniProt lists a signal peptide at residues 1–25, a chain at 26–831, four glycosylation sites, and two isoforms (UniProt Q9ULF5 processing, glycosylation, isoforms). The supplied records do not map antibody epitopes or establish isoform-specific staining or shedding. |
| How should HPA reliability affect scoring? | HPA labels tissue staining Approved but reports medium RNA concordance and pending external verification; its listed antibodies have IHC Approved status rather than an IHC Enhanced designation (HPA tissue IHC and antibody validation). Score morphology and controls alongside intensity. |
| What should IF/ICC show? | HPA ICC-IF reports mainly nucleoplasmic and cytosolic signal, with additional plasma-membrane signal; those locations are approved in that assay (HPA subcellular ICC-IF). A nuclear IF signal therefore needs its own interpretation and does not redefine the tissue IHC profile. |
| Situation | Likely cause | Next action |
|---|---|---|
| Positive-reference ciliated cells lack staining (HPA tissue IHC: High). | The run may have failed, or the section may lack intact target cells (general IHC practice). | Verify morphology and a working positive control; check primary antibody, detection reagents, and routine retrieval settings before interpreting negatives (general IHC practice). Target-specific fixation sensitivity is unreported in the supplied records. |
| Chromogen coats most of the section (general IHC practice). | Nonspecific binding or detection background may obscure the HPA cellular pattern (HPA tissue IHC profile; general IHC practice). | Compare a primary-omission control, review blocking and wash steps, and adjust antibody concentration using a known-positive section (general IHC practice). |
| Glomerular cells stain prominently (HPA tissue IHC: Not detected). | The signal conflicts with HPA’s glomerular result; endogenous activity or cross-reactivity is possible (HPA tissue IHC; general IHC practice). | Use omission and detection controls, then compare the glomerular signal with the expected positive cells (general IHC practice; HPA tissue IHC). Do not generalize this glomerular finding to proximal tubules (UniProt Q9ULF5 subcellular location). |
| Only nuclear staining is seen in tissue IHC (HPA tissue IHC profile). | It lacks the cytoplasmic and membranous tissue pattern, although HPA separately approves nucleoplasmic ICC-IF localization (HPA tissue IHC; HPA subcellular ICC-IF). | Check whether cellular boundaries and controls support the IHC signal; report the discordance instead of calling every nuclear signal artefactual (general IHC practice; HPA subcellular ICC-IF). |
| Signal is confined to lumen or extracellular material (HPA tissue IHC profile). | Acellular deposit does not match HPA’s reported cell-body or glandular staining (HPA tissue IHC); detection artefact is possible (general IHC practice). | Inspect an omission control and repeat washing or detection as needed; require staining within the expected cells for a positive call (general IHC practice; HPA tissue IHC). |
| A medium-level tissue looks weaker than the reference (HPA tissue IHC). | HPA lists several tissues at Medium, below its High ciliated-cell references (HPA tissue IHC). | Compare like cell types and section quality, then score signal above local background with controls; do not use one intensity threshold across all listed tissues (HPA tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing SLC39A10 staining
A09043-1 · IHCIHC analysis of SLC39A10 using anti-SLC39A10 antibody (A09043-1). SLC39A10 was detected in a paraffin-embedded section of human brest cancer
A09043-1 · IHCIHC analysis of SLC39A10 using anti-SLC39A10 antibody (A09043-1). SLC39A10 was detected in a paraffin-embedded section of human thyroid canc
A09043-1 · IFIF analysis of SLC39A10 using anti-SLC39A10 antibody (A09043-1). SLC39A10 was detected in an immunocytochemical section of Hela cells. Enzym
A09043 · IHCImmunohistochemistry of ZIP10 in human spleen tissue with ZIP10 antibody at 2.5 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000196950-SLC39A10/tissue/cerebral+cortex#imid_9377966
HPA · Thyroid glandHuman Protein Atlas IHC, Thyroid gland. Source: https://www.proteinatlas.org/ENSG00000196950-SLC39A10/tissue/thyroid+gland#imid_9378008
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000196950-SLC39A10/tissue/colon#imid_9352510
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000196950-SLC39A10/tissue/liver#imid_9352511
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA036512; green = SLC39A10, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA036512; green = SLC39A10, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SLC39A10 IHC & IF
🧪Run fallopian tube first; ciliated cell bodies should stain (HPA: High in fallopian tube ciliated cells). Use adipose tissue as the negative comparator (HPA: Not detected in adipocytes); on the positive slide, use adjacent cells as an internal background reference only if they are unstained (standard IHC practice).
Positive control tissue: Fallopian tube (Ciliated cells (cell body), HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SLC39A10 in A-431, U-251MG, U2OS, CACO-2, HeLa, with annotated localisation: Nucleoplasm (approved), Cytosol (approved) (HPA subcellular).
Technical controls: Run no-primary (secondary-only) and concentration-matched rabbit IgG isotype controls, matching the primary’s clonality where known (caption: rabbit primary; standard IHC practice). Test target dependence with SLC39A10 knockout material or peptide competition if the immunizing peptide is available (standard IHC practice). For the fallopian tube section, quench endogenous peroxidase and check the ciliated border for background DAB deposits (caption: HRP/DAB; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A09043-1 paraffin-section caption does not state a fixative (caption: fixative not stated). The reported IHC workflow uses heat-mediated EDTA retrieval at pH 8.0; confirm staining under the retrieval conditions used for your sections (caption: EDTA pH 8.0; standard IHC practice). Frozen sections or IF are not established as easier by the supplied evidence; score the fallopian tube’s ciliated border against the background controls, and interpret localization cautiously because ICC-IF reports mainly nucleoplasm and cytosol with additional plasma membrane signal while UniProt annotates cell and apical membranes (HPA: subcellular; UniProt Q9ULF5 localization).
HPA tissue IHC evidence for SLC39A10
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Fallopian tube | Ciliated cells (cell body) | High | Protein (IHC) | HPA → |
| Nasopharynx | Ciliated cells (cell body) | High | Protein (IHC) | HPA → |
| Bronchus | Ciliated cells (cell body) | Medium | Protein (IHC) | HPA → |
| Endometrium | Glandular cells | Medium | Protein (IHC) | HPA → |
| Lung | Alveolar cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced SLC39A10 IHC Tips
Troubleshoot SLC39A10 staining in paraffin sections by checking retrieval, cell identity and subcellular pattern alongside tissue controls.
What should I change if SLC39A10 staining is weak after antigen retrieval?
Start with heat-mediated retrieval in EDTA at pH 8.0, the condition used for the catalog antibody in a paraffin section (datasheet A09043-1). Keep section thickness, heating duration and cooling consistent across the test and control slides, then compare staining at the same primary antibody concentration. The documented section was incubated with 2 μg/ml primary antibody overnight at 4°C, so confirm those variables before changing retrieval (datasheet A09043-1). If signal remains weak, test a shorter or longer heat exposure on adjacent sections, watching for tissue damage and increased background; record the setting that improves staining in the expected cells (HPA tissue IHC).
Could fixation explain weak or uneven SLC39A10 staining?
The catalog caption describes a paraffin-embedded section but does not state its fixative, so target-specific fixation sensitivity is unknown (datasheet A09043-1). Record the fixative, fixation duration and time before processing for each specimen; compare adjacent sections processed alike before attributing a weak result to fixation. Use the documented EDTA retrieval at pH 8.0 and 2 μg/ml primary antibody as starting conditions while assessing your own material (datasheet A09043-1). If differently fixed specimens stain differently, repeat with matched controls and assess tissue preservation; neither the reported tissue distribution nor the protein's membrane topology establishes which fixation condition SLC39A10 tolerates best (HPA tissue IHC; UniProt Q9ULF5 topology).
How should I assess membranous versus cytoplasmic SLC39A10 staining?
Score cell membrane and cytoplasmic staining separately, because tissue IHC reports both patterns across several tissues (HPA tissue IHC). UniProt places SLC39A10 at the cell membrane and describes apical membrane expression in kidney proximal tubules, whereas the HPA subcellular dataset also reports cytosol and nucleoplasm (UniProt Q9ULF5 subcellular location; HPA subcellular). In a paraffin section, compare the pattern with intact cell borders and tissue architecture at the same magnification, and document whether signal is apical, lateral or diffuse. Do not treat every nuclear or cytoplasmic deposit as specific: require reproducibility in the same cell population and comparison with a negative reagent control (HPA subcellular; general IHC practice).
Can epitope placement or isoforms explain variable SLC39A10 staining?
SLC39A10 has 2 annotated isoforms, a cleaved signal sequence at residues 1–25, and 7 transmembrane segments concentrated between residues 411–821 (UniProt Q9ULF5 sequence and topology). Its annotated glycosylation sites are 139, 198, 218 and 339, so access to an epitope can plausibly depend on its position and specimen processing (UniProt Q9ULF5 glycosylation). Check the catalog antibody's stated immunogen or epitope against the isoforms before interpreting discordant staining; no epitope sequence is supplied here. Compare retrieval conditions on adjacent sections only after locating that epitope, and describe any isoform-specific interpretation as unresolved unless the antibody's binding specificity has been established (datasheet A09043-1; UniProt Q9ULF5 isoforms).
How can I check an IHC pattern by multiplex immunofluorescence?
Use IF as a separate validation experiment and pair SLC39A10 with a marker that identifies the cell population being scored in the paraffin section; HPA reports high tissue staining in ciliated cells of the fallopian tube and nasopharynx (HPA tissue IHC). Select fluorophores after imaging an unstained section, favouring channels with little tissue autofluorescence, and include single-stain controls to assess bleed-through (general IF practice). Check whether the antibody's epitope faces the extracellular space or cytosol before choosing permeabilisation, because SLC39A10 spans the membrane 7 times (UniProt Q9ULF5 topology). Compare membrane and internal fluorescence with the chromogenic pattern, while treating the catalog caption's retrieval as evidence for its paraffin IHC application only (datasheet A09043-1).
What causes diffuse brown signal when SLC39A10 controls look wrong?
First compare a no-primary control with the stained section to identify signal from the detection system, and check whether brown deposits follow damaged edges or poorly preserved areas (general IHC practice). The documented workflow used 10% goat serum blocking, a peroxidase-linked secondary antibody and DAB; those details describe the catalog antibody's paraffin-section example (datasheet A09043-1). A peroxidase block and careful washing are standard ways to address enzyme-related and nonspecific background, with block conditions established for the specimen (general IHC practice). If the no-primary control is clean, titrate the primary below the documented 2 μg/ml starting concentration and judge whether expected cell staining persists as diffuse signal falls (datasheet A09043-1; HPA tissue IHC).
How should I quantify SLC39A10 across stained tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, because HPA tissue IHC reports cytoplasmic and membranous expression in several tissues (HPA tissue IHC). For comparable regions, record the percentage of positive cells and an intensity-based H-score; report membrane and cytoplasmic scores separately if both are present (general IHC practice; HPA tissue IHC). If counting discrete positive cells, express their density per mm² of viable tissue and normalise positive counts to the number of eligible cells when cell composition differs (general IHC practice). Use matched retrieval, development time and image settings across sections, and include the same reference tissue in each staining run to assess drift (general IHC practice).
Which SLC39A10 signals are convincing rather than artefactual?
A convincing result recurs in intact cells of an expected population and gives a coherent membrane or cytoplasmic pattern; HPA reports high staining in ciliated cells of fallopian tube and nasopharynx (HPA tissue IHC). Consider the cell identity explicitly: the HPA kidney entry concerns glomerular cells reported as not detected, while UniProt describes apical expression in proximal tubules (HPA tissue IHC; UniProt Q9ULF5 subcellular location). Flag staining restricted to tissue edges, necrotic areas or no-primary controls as potential processing or detection artefact (general IHC practice). Because HPA assigns its tissue IHC data Approved reliability with medium agreement to RNA and pending external verification, confirm unexpected compartment or cell patterns with an independent control before drawing biological conclusions (HPA tissue IHC).
Boster reagents
Best SLC39A10 / Zinc transporter ZIP10 IHC Antibodies
Both catalog antibodies have human tissue IHC images; A09043-1 also has mouse and rat tissue IHC images and IF images of HeLa cells and tissue sections (catalog image captions).
Real IHC data
Anti-SLC39A10 Antibody ®
Cat # A09043-1
Real IHC data
Anti-ZIP10 SLC39A10 Antibody
Cat # A09043
A09043 has IHC-P listed and an IHC image of human spleen at 2.5 μg/mL (catalog application list; A09043 image caption). A09043-1 has paraffin-section IHC images of human breast and thyroid cancer and mouse and rat brain, plus IF images of HeLa cells and human, mouse and rat tissue sections (A09043-1 image captions).
Which to pick: For paraffin-section tissue IHC, choose A09043-1 when a captioned retrieval and detection workflow is useful; its IHC captions specify EDTA retrieval, goat serum blocking and DAB detection, but do not report the fixative (A09043-1 IHC image captions). For IF/ICC, choose A09043-1 because those applications and corresponding images are listed for it (A09043-1 application list; IF image captions). For mouse or rat tissue IHC, A09043-1 has species-specific images; A09043 lists mouse and rat reactivity but its supplied IHC image is human spleen, and clonality is unreported for both (catalog reactivity; image captions; clone fields).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9ULF5 (S39AA_HUMAN, Zinc transporter ZIP10).
- Human Protein Atlas. SLC39A10 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. SLC39A10 subcellular location (ICC-IF): Mainly localized to the nucleoplasm and cytosol. In addition localized to the plasma membrane..
- Human Protein Atlas. SLC39A10 antibody validation summary (3 antibodies).
- SLC39A10 Upregulation Predicts Poor Prognosis, Promotes Proliferation and Migration, and Correlates with Immune Infiltration in Hepatocellular Carcinoma. Journal of hepatocellular carcinoma 2021 — PMC8357404.
- TLR4 promotes ESCC progression by driving inflammation and metabolic reprogramming through SLC39A10-mediated zinc homeostasis. Journal of translational medicine 2026 — PMC12869945.
- SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways. Experimental & molecular medicine 2023 — PMC10474099.
- SLC39A10 drives M2 macrophage polarization and gastric cancer progression through the MAPK14(p38α) pathway. iScience 2026 — PMC12796609.
- PubMed PMID:10574462 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:17974005 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SLC39A10 (Zinc transporter ZIP10). Expected localisation Cytoplasmic and membranous tissue staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A09043-1). Validated IHC antibody: A09043-1 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Fallopian tube (Ciliated cells (cell body)); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human brest cancer tissue; fixative not specified (datasheet A09043-1); 2. Fixation: Image fixative and duration unreported (datasheet A09043-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A09043-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A09043-1); 8. Primary antibody: Rabbit anti-SLC39A10, 2-5 μg/ml (datasheet A09043-1); 9. Primary incubation: Overnight at 4 °C (datasheet A09043-1). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A09043-1); Caveat: Medium staining–RNA consistency; verify the signal (HPA tissue IHC); Isoform / epitope: 2 isoforms; confirm extracellular vs cytoplasmic epitope (UniProt); Regulation: Expression regulation is not annotated (UniProt). Evidence: UniProt Q9ULF5, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the nucleoplasm and cytosol. In addition…, Datasheet A09043-1, PMC8357404. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SLC39A10/immunohistochemistry-ihc-guide.